ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Aquestive Therapeutics (AQST)
Aquestive Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · NASDAQ
$4.07▲ +2.52%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Aquestive Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Aquestive Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Aquestive Therapeutics a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $3.60 and $4.50; in 9 out of 10, between $2.95 and $5.49. Estimated annual volatility is 61%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $571M
- 52-week high
- $7.05
- 52-week low
- $2.93
- Revenue (12 months)
- $54.1M
- Revenue growth (YoY)
- -22.6%
- Gross margin
- 58.4%
- Operating margin
- -159.5%
- Net margin
- -188.1%
- Return on equity
- 248.9%
- Free cash flow (12 months)
- $-26.9M
- Beta
- 1.47
What this means
ATLAS does not publish a fair value for AQST right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks AQST has traded between $2.93 and $7.05. Today it is 42.3% below that high and 39% above its low.
On the business: revenue fell 22.6% year over year; net margin is 188.1%.
Its beta is 1.47: it tends to move more than the market, both up and down.
About the company
Aquestive Therapeutics Inc. is a specialty pharmaceutical company focused on developing and commercializing oral and non-invasive drug-delivery therapies.
Want to see everything about Aquestive Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Aquestive Therapeutics do?
Aquestive Therapeutics Inc. is a specialty pharmaceutical company focused on developing and commercializing oral and non-invasive drug-delivery therapies.
What is the chance AQST goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, AQST ends the month between $3.60 and $4.50.
How big is Aquestive Therapeutics and what is its P/E ratio?
Aquestive Therapeutics's market capitalization is $571M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is AQST?
ATLAS estimates annual volatility at 61%. In a typical month, half of the outcomes end between $3.60 and $4.50.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer